DK1326634T3 - Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber - Google Patents
Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaberInfo
- Publication number
- DK1326634T3 DK1326634T3 DK01980496T DK01980496T DK1326634T3 DK 1326634 T3 DK1326634 T3 DK 1326634T3 DK 01980496 T DK01980496 T DK 01980496T DK 01980496 T DK01980496 T DK 01980496T DK 1326634 T3 DK1326634 T3 DK 1326634T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- antigen
- amino acid
- acid residue
- vaccine composition
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- 230000033289 adaptive immune response Effects 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000007970 thio esters Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0178900A AT410635B (de) | 2000-10-18 | 2000-10-18 | Vakzin-zusammensetzung |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1326634T3 true DK1326634T3 (da) | 2006-08-14 |
Family
ID=3688953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01980496T DK1326634T3 (da) | 2000-10-18 | 2001-10-18 | Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber |
Country Status (27)
Country | Link |
---|---|
US (3) | US8361476B2 (fr) |
EP (1) | EP1326634B1 (fr) |
JP (2) | JP4227407B2 (fr) |
KR (1) | KR100598302B1 (fr) |
CN (1) | CN1248736C (fr) |
AT (2) | AT410635B (fr) |
AU (2) | AU2002212326B2 (fr) |
BR (1) | BRPI0114994B8 (fr) |
CA (1) | CA2426490C (fr) |
CZ (1) | CZ303303B6 (fr) |
DE (1) | DE60119145T2 (fr) |
DK (1) | DK1326634T3 (fr) |
ES (1) | ES2263668T3 (fr) |
HK (1) | HK1055899A1 (fr) |
HU (1) | HU228382B1 (fr) |
IL (2) | IL154605A0 (fr) |
IS (1) | IS2608B (fr) |
MX (1) | MXPA03002828A (fr) |
NO (1) | NO330274B1 (fr) |
NZ (1) | NZ524532A (fr) |
PL (1) | PL209016B1 (fr) |
PT (1) | PT1326634E (fr) |
RU (2) | RU2328305C2 (fr) |
SI (1) | SI1326634T1 (fr) |
SK (1) | SK287618B6 (fr) |
WO (1) | WO2002032451A1 (fr) |
ZA (1) | ZA200301465B (fr) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
CA2433794A1 (fr) * | 2001-01-05 | 2002-07-11 | Intercell Ag | Utilisations de composes polycationiques |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
EP1279404A1 (fr) * | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Utilisation de HIV-1 tat fragments ou dérivés pour activer des cellules présentatrices d'antigènes, pour délivrer des molécules cargo pour la vaccination ou pour le traitement d'autres maladies |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
AU2003254585A1 (en) | 2002-07-24 | 2004-02-16 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
AU2003258672B2 (en) | 2002-09-13 | 2008-10-30 | Intercell Ag | Method for isolating hepatitis C virus peptides |
AU2003274011B2 (en) | 2002-10-15 | 2010-03-04 | Intercell Ag | Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof |
CN1756843B (zh) | 2003-03-04 | 2012-03-21 | 英特塞尔股份公司 | 化脓链球菌抗原 |
AU2004224746B2 (en) * | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
AU2004224747A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Use of Alum and a th1 immune response inducing adjuvant for enhancing immune responses |
EP2182065A3 (fr) | 2003-03-31 | 2010-09-15 | Intercell AG | Antigènes du Staphylococcus epidermidis |
AU2004230244B2 (en) | 2003-04-15 | 2011-09-22 | Intercell Ag | S. pneumoniae antigens |
US8076059B2 (en) * | 2003-04-16 | 2011-12-13 | Duke University | Adjuvant capable of specifically activating the adaptive immune response |
CN101864432A (zh) | 2003-05-07 | 2010-10-20 | 英特塞尔股份公司 | 无乳链球菌抗原ⅰ和ⅱ |
US20080175856A1 (en) | 2003-05-30 | 2008-07-24 | Intercell Ag | Enterococcus Antigens |
CN1822856B (zh) * | 2003-07-11 | 2010-04-28 | 英特塞尔股份公司 | Hcv疫苗 |
WO2005094891A2 (fr) | 2004-03-12 | 2005-10-13 | Intercell Ag | Procede de solubilisation de melanges de peptides |
ES2344739T3 (es) | 2004-09-24 | 2010-09-06 | Intercell Ag | Proteina capsidial vp1 modificada del parvovirus b19. |
DK1931379T3 (da) | 2005-10-07 | 2013-08-19 | Sec Dep For Health | Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
EP2402024A1 (fr) | 2006-06-28 | 2012-01-04 | Statens Serum Institut | Expansion du répertoire de lymphocytes T pour inclure des épitomes sous-dominants par la vaccination avec des antigènes administrés sous forme de fragments de protéines ou de cocktails de peptides |
JP2009542196A (ja) | 2006-07-07 | 2009-12-03 | インターセル アーゲー | 小型の化膿連鎖球菌抗原およびそれらの使用 |
CA2661224A1 (fr) | 2006-09-15 | 2008-03-20 | Intercell Ag | Antigenes de borrelia |
EP1923069A1 (fr) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protecteurs contre S. pneumoniae et compositions, méthodes et utilisations associés |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
CA2675379A1 (fr) | 2007-01-12 | 2008-07-17 | Intercell Ag | Proteines protectrices de s. agalactia, leurs combinaisons et leurs procedes d'utilisation |
EP2489673A3 (fr) | 2007-05-02 | 2012-09-12 | Intercell AG | Antigènes de Klebsiella |
EP2158211B1 (fr) | 2007-05-31 | 2016-08-10 | Medigene AG | Protéine structurale mutée d'un parvovirus |
EP2012122A1 (fr) | 2007-07-06 | 2009-01-07 | Medigene AG | Protéines structurelles de parvovirus muté |
JP2010530229A (ja) | 2007-06-18 | 2010-09-09 | インターセル アーゲー | クラミジア属の抗原 |
CA2718473A1 (fr) | 2008-03-17 | 2009-09-24 | Intercell Ag | Peptides luttant contre s. pneumoniae et compositions, methodes et utilisations associees |
US8287887B2 (en) | 2008-04-02 | 2012-10-16 | The University Of Tokushima | Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same |
WO2009155484A2 (fr) | 2008-06-20 | 2009-12-23 | Wyeth | Compositions et procédés d'utilisation d'orf1358 provenant de souches de streptocoques bêta-hémolytiques |
US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
EP2424882A2 (fr) | 2009-02-05 | 2012-03-07 | Intercell AG | PEPTIDES PROTECTEURS CONTRE E. FAECALIS, PROCÉDÉS ET UTILISATIONS LIÉS À CEUX-CI& xA; |
EP2405938A2 (fr) | 2009-02-13 | 2012-01-18 | Intercell AG | Antigenes haemphilus influenzae non typables |
EP3461496B1 (fr) | 2009-06-22 | 2023-08-23 | Wyeth LLC | Compositions et procédés d'élaboration de compositions immunogènes conjuguées à polysaccharides capsulaires de sérotypes 5 et 8 de staphylococcus aureus |
MX2012000044A (es) | 2009-06-22 | 2012-01-30 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus. |
EP2470205A1 (fr) | 2009-08-27 | 2012-07-04 | Novartis AG | Adjuvant contenant de l'aluminium, un oligonucléotide et une polycation |
EP2319871A1 (fr) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant |
WO2011042548A1 (fr) | 2009-10-09 | 2011-04-14 | Sanofi-Aventis | Polypeptides de liaison au « récepteur de produits terminaux de glycation avancée » ainsi que compositions et procédés les mettant en jeu |
EP2308896A1 (fr) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant |
WO2011101465A1 (fr) | 2010-02-19 | 2011-08-25 | Intercell Ag | Nanoparticules d'ic31 |
JP2013522287A (ja) | 2010-03-18 | 2013-06-13 | ノバルティス アーゲー | 血清群b髄膜炎菌のためのアジュバント添加ワクチン |
SI3170508T1 (sl) | 2010-06-04 | 2020-01-31 | Wyeth Llc | Formulacije cepiva |
PT3246044T (pt) | 2010-08-23 | 2021-02-15 | Wyeth Llc | Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis |
JP6121421B2 (ja) | 2010-09-03 | 2017-04-26 | バルネバ オーストリア ジーエムビーエイチ | C.ディフィシルの毒素aおよび毒素bタンパク質の単離ポリペプチドならびにその使用 |
AR082925A1 (es) | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
ES2614815T3 (es) | 2010-12-22 | 2017-06-02 | Wyeth Llc | Composiciones inmunogénicas estables de antígenos de Staphylococcus aureus |
BRPI1100857A2 (pt) * | 2011-03-18 | 2013-05-21 | Alexandre Eduardo Nowill | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
NZ628449A (en) | 2012-03-09 | 2016-04-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
JP6445427B2 (ja) * | 2012-05-08 | 2018-12-26 | ウエスタン ユニバーシティ オブ ヘルス サイエンシズ | CD4+T細胞集団の抗原特異的な拡大のために標準化されたexvivoプラットフォーム |
MY202024A (en) * | 2012-10-29 | 2024-03-29 | Univ Arkansas | Novel mucosal adjuvants and delivery systems |
PL3363806T3 (pl) | 2012-12-20 | 2022-12-19 | Pfizer Inc. | Sposób glikokoniugacji |
US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
US20140271723A1 (en) * | 2013-03-15 | 2014-09-18 | Saint Louis University | Adjuvant compositions and methods of using thereof |
EP4098276A1 (fr) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Compositions utilisables contre neisseria meningitidis et procédés associés |
WO2016130569A1 (fr) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | Composition contenant des antigènes du vdep et procédés de fabrication et d'utilisation de la composition |
KR20170103009A (ko) | 2015-02-19 | 2017-09-12 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
IL255106B2 (en) | 2015-05-04 | 2023-04-01 | Pfizer | Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses |
CN107446019B (zh) * | 2016-07-01 | 2021-10-15 | 四川大学 | 抗菌肽衍生物及其用途 |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
CN118021947A (zh) | 2017-01-31 | 2024-05-14 | 辉瑞大药厂 | 脑膜炎奈瑟菌组合物及其使用方法 |
CN107266585B (zh) * | 2017-07-13 | 2019-08-06 | 陕西科技大学 | 一种mlh融合抗菌肽及其制备方法和应用 |
EP3527223A1 (fr) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Protéine structurelle de parvovirus muté |
WO2019158636A1 (fr) | 2018-02-16 | 2019-08-22 | 2A Pharma Ab | Protéine structurale de parvovirus pour le traitement de maladies auto-immunes |
CN109745556A (zh) * | 2019-03-01 | 2019-05-14 | 龙阔(苏州)生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
PE20220400A1 (es) | 2019-05-20 | 2022-03-22 | Valneva Se | Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio |
WO2021202456A1 (fr) * | 2020-03-30 | 2021-10-07 | The Wistar Institute Of Anatomy And Biology | Mimétiques de récepteurs solubles synthétiques et procédés d'utilisation pour le traitement de la covid-19 |
US20230146256A1 (en) | 2020-04-17 | 2023-05-11 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
EP4203995A1 (fr) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Conjugués polysaccharide-protéine de streptococcus du groupe b, procédés de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations |
EP4319802A2 (fr) | 2021-04-09 | 2024-02-14 | Valneva SE | Vaccin combiné contre le métapneumovirus humain |
WO2023083964A1 (fr) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Protéine structurale de parvovirus dirigée contre hpv bêta-et gamma |
WO2024069420A2 (fr) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Compositions immunogènes comprenant un trimère de protéine f rsv |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ271774A (en) * | 1993-08-06 | 1998-02-26 | Cytel Corp | Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen |
JP3442824B2 (ja) * | 1993-08-30 | 2003-09-02 | 理化学研究所 | 抗菌性ペプチド類 |
JP3547504B2 (ja) * | 1994-11-01 | 2004-07-28 | 独立行政法人理化学研究所 | 新規なポリペプチド及びその用途 |
WO1998056931A1 (fr) * | 1997-06-11 | 1998-12-17 | Institut Pasteur | Mycobacteries de recombinaison attenuees utilisables comme immunogenes ou composants vaccinaux |
AU760034B2 (en) * | 1997-08-29 | 2003-05-08 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
CU22700A1 (es) * | 1997-09-29 | 2001-07-31 | Ct Ingenieria Genetica Biotech | Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso |
US20020072495A1 (en) * | 2000-09-21 | 2002-06-13 | Oleg Chertov | LL-37 is an immunostimulant |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
AU2004224747A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Use of Alum and a th1 immune response inducing adjuvant for enhancing immune responses |
AU2004224746B2 (en) * | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
CN1822856B (zh) * | 2003-07-11 | 2010-04-28 | 英特塞尔股份公司 | Hcv疫苗 |
-
2000
- 2000-10-18 AT AT0178900A patent/AT410635B/de not_active IP Right Cessation
-
2001
- 2001-10-18 SI SI200130564T patent/SI1326634T1/sl unknown
- 2001-10-18 ES ES01980496T patent/ES2263668T3/es not_active Expired - Lifetime
- 2001-10-18 PT PT01980496T patent/PT1326634E/pt unknown
- 2001-10-18 CZ CZ20031299A patent/CZ303303B6/cs not_active IP Right Cessation
- 2001-10-18 BR BRPI0114994-6 patent/BRPI0114994B8/pt not_active IP Right Cessation
- 2001-10-18 DE DE60119145T patent/DE60119145T2/de not_active Expired - Lifetime
- 2001-10-18 RU RU2003114434/15A patent/RU2328305C2/ru active
- 2001-10-18 EP EP01980496A patent/EP1326634B1/fr not_active Expired - Lifetime
- 2001-10-18 CA CA2426490A patent/CA2426490C/fr not_active Expired - Lifetime
- 2001-10-18 AU AU2002212326A patent/AU2002212326B2/en not_active Expired
- 2001-10-18 WO PCT/EP2001/012041 patent/WO2002032451A1/fr active IP Right Grant
- 2001-10-18 DK DK01980496T patent/DK1326634T3/da active
- 2001-10-18 PL PL362966A patent/PL209016B1/pl unknown
- 2001-10-18 CN CNB018171168A patent/CN1248736C/zh not_active Expired - Lifetime
- 2001-10-18 HU HU0302117A patent/HU228382B1/hu unknown
- 2001-10-18 KR KR1020037004977A patent/KR100598302B1/ko active IP Right Grant
- 2001-10-18 US US10/399,442 patent/US8361476B2/en active Active
- 2001-10-18 JP JP2002535688A patent/JP4227407B2/ja not_active Expired - Lifetime
- 2001-10-18 SK SK575-2003A patent/SK287618B6/sk not_active IP Right Cessation
- 2001-10-18 IL IL15460501A patent/IL154605A0/xx unknown
- 2001-10-18 AT AT01980496T patent/ATE324116T1/de not_active IP Right Cessation
- 2001-10-18 MX MXPA03002828A patent/MXPA03002828A/es active IP Right Grant
- 2001-10-18 AU AU1232602A patent/AU1232602A/xx active Pending
- 2001-10-18 NZ NZ524532A patent/NZ524532A/en not_active IP Right Cessation
-
2003
- 2003-02-20 IS IS6722A patent/IS2608B/is unknown
- 2003-02-24 ZA ZA200301465A patent/ZA200301465B/en unknown
- 2003-02-24 IL IL154605A patent/IL154605A/en unknown
- 2003-04-08 NO NO20031595A patent/NO330274B1/no not_active IP Right Cessation
- 2003-11-12 HK HK03108189A patent/HK1055899A1/xx not_active IP Right Cessation
-
2007
- 2007-12-13 RU RU2007146372/15A patent/RU2007146372A/ru not_active Application Discontinuation
-
2008
- 2008-05-21 US US12/124,785 patent/US8900564B2/en active Active
- 2008-05-22 JP JP2008134215A patent/JP2008222721A/ja not_active Withdrawn
-
2013
- 2013-01-16 US US13/742,500 patent/US20130216583A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1326634T3 (da) | Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber | |
PL324531A1 (en) | Derivatives of cyclosporin effective against hiv virus | |
RU2003114434A (ru) | Вакцинная композиция | |
ATE429448T1 (de) | Peptidzusammensetzung als immunogen zur allergiebehandlung. | |
ATE442378T1 (de) | Substituierte wt1-peptide | |
ZA200207992B (en) | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid for induction of an immune response to amyloid and amyloid deposits. | |
ATE557041T1 (de) | Peptid-vakzinen gegen streptokokken der gruppe a | |
PT1290013E (pt) | Derivados dos peptidos apo-ai/aii | |
CY1108570T1 (el) | Gd3-μιμητικα πεπτιδια | |
DE60144561D1 (de) | N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide | |
BR0309491A (pt) | Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes | |
SE9002684D0 (sv) | New peptides and their use | |
ES2176334T3 (es) | El uso de gabapentin en el tratamiento de la ansiedad y el panico. | |
MXPA02012664A (es) | Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis. | |
EA200100314A1 (ru) | Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины | |
WO1994004565A3 (fr) | Vaccin vnpi | |
WO2001074847A3 (fr) | Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer | |
AR009840A1 (es) | Preparado vacunal para la inmunocastracion revesible de mamiferos | |
ECSP003720A (es) | Peptidos modificados y peptidomimeticos para el uso en inmunoterapia | |
SE0002738D0 (sv) | Electric actuator |